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Summary 32 
Macromorphological analysis of skeletons, from 20 selected graves of the 8th century AD 33 
Bélmegyer-Csömöki domb, revealed 19 cases of possible skeletal tuberculosis. Biomolecular 34 
analyses provided general support for such diagnoses, including the individual without pathology, 35 
but the data did not show coherent consistency over the range of biomarkers examined. 36 
Amplification of ancient DNA fragments found evidence for the Mycobacterium tuberculosis 37 
complex DNA only in five graves. In contrast, varying degrees of lipid biomarker presence were 38 
recorded in all except two of the skeletons, though most lipid components appeared to be somewhat 39 
degraded. Mycobacterial mycolic acid biomarkers were absent in five cases, but the weak, possibly 40 
degraded profiles for the remainder were smaller and inconclusive for either tuberculosis or leprosy. 41 
The most positive lipid biomarker evidence for tuberculosis was provided by mycolipenic acid, with 42 
13 clear cases, supported by five distinct possible cases. Combinations of mycocerosic acids were 43 
present in all but three graves, but in one case a tuberculosis-leprosy co-infection was indicated. In 44 
two specimens with pathology, no lipid biomarker evidence was recorded, but one of these 45 
specimens provided M. tuberculosis complex DNA fragments.  46 
 47 
Key words: ancient DNA; lipid biomarkers; Mycobacterium tuberculosis complex; 48 
palaeopathology; PCR 49 
  50 
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1. Introduction 51 
The macromorphological diagnosis of skeletal tuberculosis (TB) in human remains is based upon 52 
the detection of secondary skeletal lesions.1 The most common representation of skeletal TB is 53 
spondylitis tuberculosa, which affects the vertebral column. After vertebral involvement, the second 54 
most frequent alteration in TB is arthritis of the large, weight-bearing joints.2 Initially, the diagnosis 55 
of TB in osteoarchaeological samples focused only on these classical TB lesions, representing a 56 
fairly developed stage of tuberculosis. However, TB may have affected many individuals without 57 
classical pathological changes, thus patients died in an earlier stage of tuberculosis long before 58 
these symptoms could have developed. Clearly, this early-stage TB is not recognizable on the basis 59 
of classical TB alterations, so if we consider only individuals with visible TB-related lesions, it is 60 
likely this will significantly underestimate the prevalence of tuberculosis in the examined historical 61 
populations.1,3 62 
Because of the problems of tuberculosis diagnostics, the importance of establishing diagnostic 63 
criteria for early-stage TB became recognized in the late 20th century. A number of studies – mainly 64 
based on the examination of skeletal collections with known causes of death – have focused on 65 
searching for atypical or early-stage lesions in connection with tuberculosis infection. These 66 
investigations enabled the recognition of three types of atypical or early-stage TB alterations: rib 67 
lesions, superficial vertebral changes including hypervascularisation, and endocranial alterations.3-7 68 
Positive correlations between tuberculosis and stress indicators, such as long bone periostitis, cribra 69 
orbitalia and cribra cranii, were also recognized.7,8 Since the 1990s, the identification of skeletal 70 
tuberculosis in ancient human remains has been facilitated by the confirmation of atypical or early-71 
stage TB lesions by new biomolecular methods based on mycobacterial ancient DNA (aDNA) and 72 
lipid biomarker analyses.1,9-12 73 
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In 1990, the first paleopathological analyses of the 8th century AD series Bélmegyer-Csömöki 74 
domb were essentially based on macromorphological and radiological examinations, biomolecular 75 
methods were used only in a few cases. From a macromorphological point of view, those 76 
investigations only considered classical TB alterations.9,13,14,15 An advanced-age female skeleton 77 
from the grave No. 65 showed severe osteolytic lesions of the anterior portion of the thoracic and 78 
lumbar vertebral bodies, causing an unequal collapse, which led to angular kyphosis (Suppl. Fig. S1 79 
a-b).14 Mycobacterial DNA targets IS6110 and the 65-kDa antigen gene, of the Mycobacterium 80 
tuberculosis complex (MTBC), were found in samples from this specimen.9 In another case, of a 81 
mature male individual (grave No. 90), the pathological remodelling and fusion of the lumbosacral 82 
region and the irregular ante-mortem erosion on the ventral surface of the sacrum, support the 83 
diagnosis of a lumbo-sacral tuberculous involvement with cold abscess. In addition, the severe 84 
destruction both of the left hip bone and proximal femur is suggestive of tuberculous arthritis or 85 
coxitis tuberculosa (Suppl. Fig. S1 c-d).15 The diagnosis of skeletal TB was confirmed by 86 
biomolecular results, the identification of the DNA-fragment (65-kDa antigen gene) of the MTBC 87 
was successful.9 In a further case, the complete ankylosis of the right knee indicated gonitis 88 
tuberculosa of an elderly male individual from grave No. 215.13 89 
Marcsik and co-workers published two further classical TB cases in 2007.16 A young female 90 
skeleton from grave No. 38 exhibited signs of probable tuberculous arthritis (coxitis tuberculosa) of 91 
the right hip joint. Skeletal remains of an adult male individual (grave No. 189) presented complete 92 
ankylosis of the 9th and 10th thoracic vertebrae and fusion of the 1st and 2nd and the 3rd and 4th 93 
lumbar vertebrae. In addition, new bone formation and osteophytes were found on the ventral 94 
surfaces of all lumbar vertebral bodies. These alterations suggest the diagnosis of spondylitis 95 
tuberculosa.16 96 
The above mentioned former investigations of the series from the Bélmegyer-Csömöki domb 97 
have provided interesting paleopathological cases of skeletal tuberculosis. However, the complete 98 
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skeletal material has never been analysed systematically for both classical and early-stage TB 99 
lesions, and biomolecular analyses had been undertaken only in a few cases. The recent 100 
development of diagnostic criteria in the field of paleopathology of TB and biomolecular methods 101 
for detection of the MTBC encouraged us to perform a re-examination of the series from 2009. The 102 
aim of this study is to summarize the results of this re-examination. 103 
2. Material and Methods 104 
2.1 Archaeological background 105 
The skeletal material for this study derives from the archaeological site of the Bélmegyer-106 
Csömöki domb, rising about three kilometres south-east of the village Bélmegyer, in South-Eastern 107 
Hungary. During a long-running excavation (1985 – 1989), skeletal remains of 240 individuals 108 
were unearthed. On the basis of the grave goods found in the completely excavated cemetery, it was 109 
used for burials between 670 – 800 AD during the late Avar Period.17,18 110 
Our research strategy was to combine different diagnostic methods in order to get independent 111 
verification using different biomarkers. First we conducted the morphological analysis of the 112 
skeletal series. Next, bone samples were taken from the skeletal remains of the suspected TB cases. 113 
Small pieces from the same rib were selected and sent to separate centres for the aDNA and lipid 114 
biomarker analyses. 115 
2.2 Macromorphological analysis 116 
The paleopathological examination of the mostly well-preserved skeletal remains of the 240 117 
individuals (95 males, 72 females, 73 undeterminable) was carried out in the Department of 118 
Biological Anthropology, University of Szeged, Hungary. These investigations were performed 119 
using macromorphological methods, focussing on previously detailed classical2 and atypical TB 120 
alterations.3-7  121 
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2.3 Mycobacterial aDNA analysis 122 
2.3.1 Mycobacterial DNA extraction 123 
Possible cases of skeletal TB, defined according to skeletal morphological alterations, were 124 
examined for the presence of aDNA from the Mycobacterium tuberculosis complex (MTBC). 125 
Recommended protocols for aDNA work were followed19 with separate rooms and equipment for 126 
different stages of the process. Well-established methods were employed for aDNA extraction and 127 
amplification20-27 as detailed in Donoghue et al in this volume28 and in Supplementary data. The 128 
approach used was of a slow but thorough period of sample disruption, one aliquot treated with N-129 
phenacylthiozolium bromide (PTB), to cleave any covalent cross-links thus facilitating DNA strand 130 
separation and amplification.21 Subsequently, samples were treated with guanidium thiocyanate, 131 
followed by sample and bacterial cell disruption, using boiling and snap-freezing in liquid nitrogen. 132 
All fractions of the sample were used in the extraction. DNA was captured with silica and the 133 
pelletswashed and dried.28 Silica supernates from PTB-negative samples were also processed by 134 
removal of protein followed by DNA precipitation with isopropanol (−20 oC).28 Dried samples were 135 
re-hydrated with elution buffer and used immediately or stored at −20 oC. Negative extraction 136 
controls were processed in parallel with the test samples. 137 
2.3.2  DNA amplification and detection 138 
Two specific regions of the M. tuberculosis complex were targeted – the repetitive elements 139 
IS6110 (1–25 copies/cell) and IS1081 (6 copies/cell). The IS6110 primers used for conventional 140 
PCR had a target region of 123 bp22 and the IS1081 primers produce an amplicon of 113 bp.23 141 
Later, specific M. tuberculosis primers and a fluorescent probe were used24 to enable shorter DNA 142 
fragments to be detected in a real-time PCR reaction (Supplementary data). 143 
2.3.3 The PCR conditions 144 
The PCR mix included 2mM bovine serum albumin to reduce PCR inhibition25 and 2.0mM 145 
MgCl2. PCR assays were initially run at an annealing temperature of 58oC and amplified DNA was 146 
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examined by agarose gel electrophoresis.26 Subsequently, amplification was performed in a final 147 
volume of 25µl using a RotorGene© 3000 (Qiagen) real-time platform27 to enable the detection of 148 
DNA using SYBR Green and melt analysis or specific primers with fluorescent probe. Annealing 149 
was at 60oC. A hot-start Taq polymerase was used to minimize non-specific primer and template 150 
binding. Negative DNA extraction and PCR controls were processed alongside the test samples. 151 
2.4 Lipid Biomarker Analysis 152 
Details of the methods and analysis are given in the Supplementary data. Specimens were 153 
hydrolysed by heating with 30% potassium hydroxide in methanol (2ml) and toluene (1ml) at 100ºC 154 
overnight.11,29 In parallel, standard biomass of M. tuberculosis and M. leprae was processed. Long-155 
chain compounds were extracted as described previously29 and the extract was treated with 156 
pentafluorobenzyl bromide, under phase-transfer conditions11,29 to convert acidic components into 157 
pentafluorobenzyl (PFB) esters. Subsequent separation on an Alltech 209250 (500mg) normal phase 158 
silica gel cartridge gave fractions containing non-hydroxylated fatty acid PFB esters, mycolic acid 159 
(MA) PFB esters and free phthiocerols.11,29 The MA PFB esters reacted with pyrenebutyric acid 160 
fi(PBA) to produce PBA-PFB MA derivatives, which were purified on an Alltech 205250 (500mg) 161 
C18 reverse phase cartridge.11,29  The PBA-PFB mycolates were analysed by reverse phase HPLC, 162 
as described previously.11,29 The non-hydroxylated PFB ester fractions were refined on an Alltech 163 
205250 (500mg) reverse phase silica gel cartridge, using a water-methanol/methanol/methanol-164 
toluene elution sequence.29 A fraction enriched in mycocerosic acid and other longer chain (> C20) 165 
PFB esters was eluted by 100% methanol with the more usual C12 to C20 esters eluting in the earlier 166 
water/methanol fractions. The fractions containing possible mycocerosates, were analysed by 167 
negative ion chemical ionization gas chromatography mass spectrometry (NICI-GCMS), as 168 
previously described.29 169 
3. Results 170 
3.1 Macromorphological analysis 171 
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During the macromorphological analysis of the skeletal material of the Bélmegyer-Csömöki 172 
domb, 19 cases of probable skeletal tuberculosis were detected. Classical TB changes were 173 
observed in the five cases detailed above in the Introduction (Suppl. Fig. S1 a-d; Table 1), while 174 
atypical or early-stage TB lesions were observed in a further 14 cases (Suppl. Fig. S2 a-c; Table 1). 175 
It is clear, therefore, that these atypical or early TB changes occurred significantly more often than 176 
the classical alterations. Only grave No. 86 showed no macromorphological evidence of 177 
tuberculosis (Table 1). 178 
The most frequent lesions were periosteal reactions on the visceral rib surfaces and abnormal 179 
vertebral vascularisation. Ten cases of superficial vertebral changes were detected (Table 1). With 180 
the exception of three specimens (two mature males and one elderly female), the affected 181 
individuals belong to younger age groups: one Infans II, three juveniles and three young adult 182 
males. Eight individuals exhibited hypervascularisation of the anterior aspect of vertebral bodies, 183 
while lytic vertebral lesions were revealed in only two cases. 184 
As for rib changes, eight individuals (one juvenile, four adults, two mature and one elderly) 185 
showed signs of periosteal appositions on the visceral costal surfaces (Table 1). In the majority of 186 
the cases, rib periostitis showed a woven-remodelled character, indicating a less active process 187 
generating these pathological changes. In two other cases (grave No. 17 and grave No. 212) it was 188 
noticed that the visceral surfaces of ribs had a roughened texture.  189 
Endocranial alterations were revealed in five individuals only (Table 1). Except for a mature 190 
male specimen (grave No. 33), the affected individuals represent younger age groups: one juvenile 191 
and three young adults (one male and two females). Concerning lesion morphology, abnormal 192 
blood vessel impressions on the internal surface of the skull were observed in three of the five 193 
cases, though the endocranial lamina of grave No. 22 exhibited small granular impressions similar 194 
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to those described by Schultz5 and in the skeleton of a young adult female individual (grave No. 195 
233) serpens endocrania symmetrica (SES) was identified.  196 
With the exception of two cases (grave No. 88 and grave No. 188), an association of different 197 
alterations could be detected. Atypical or early-stage TB changes were accompanied by stress 198 
factors in a number of cases: cribra orbitalia (mainly the porotic form) was observed in seven 199 
cases, while long bone periostitis occurred in six cases (Table 1). Long bone periostitis appeared 200 
mostly on femora and tibiae, but in three cases the long bones of the upper extremities were also 201 
affected.  202 
3.2 Biomolecular Analyses 203 
The aDNA amplification studies gave positive results for nine of the 20 graves investigated, but 204 
for only one of the four “classical TB cases” (Table 1). Full data of the aDNA analysis are provided 205 
in Supplementary data. Total mycolic acid (MA) profiles are recorded in Fig. 1 that also includes a 206 
summary of the overall lipid biomarker and aDNA results. All the MA profiles were too weak to 207 
allow further diagnostic analyses, by sequential normal and reverse phase HPLC.11,29 Material from 208 
five graves (Nos. 33, 66, 154, 188, 212) yielded no MAs.  Fig. 2 shows three representative profiles 209 
of mycolipenic (ML) and mycocerosic (MC) acids; full data are provided in Supplementary Figures 210 
S3, S4 and S5. 211 
The results of the lipid biomarker analyses could be placed into 6 groups (Table 1, Figs. S3-5). 212 
Group 1 (grave Nos. 22, 86, 88, 134) had clear evidence of all three MA, ML and MC lipid 213 
biomarker classes; grave No. 22, however, also included C33 and C34 mycocerosates, indicative of 214 
leprosy. The major Group 2 (grave Nos. 12, 17, 48, 65, 90, 189, 215) was characterised by the 215 
presence of a clear signal for mycolipenate (ML), with less convincing evidence for the other MA 216 
and MC classes. Group 3 (grave Nos. 66, 188) had two representatives with good ML, weak MCs, 217 
but no MA; a single member of Group 4 (grave No. 154) had only a poor ML signal. Four 218 
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representatives in Group 5 (grave Nos. 38, 92, 116, 233) provided weak inconclusive evidence for 219 
ML and MC biomarkers. Final Group 6 (grave Nos. 33, 212) lacked any evidence of mycobacterial 220 
lipid biomarkers. A close correlation with the aDNA data was not observed. Only one (grave No. 221 
88) of four in the best Group 1 lipid class gave amplified DNA. Correlation was better for the 222 
Group 2 lipid class with four of seven having aDNA. In the less strong or negative lipid Groups 3-6, 223 
only one grave in each group had a positive aDNA result.  224 
4. Discussion and conclusions 225 
In 19 out of the 20 skeletons from Bélmegyer-Csömöki domb a range of macromorphological 226 
changes, indicative of tuberculosis, were observed. Only nine of the 20 graves yielded M. 227 
tuberculosis aDNA on amplification. Lipid biomarker evidence for M. tuberculosis was discerned 228 
in all but two of the specimens, but the strength and conclusiveness of the lipid signals could be 229 
allocated to five levels (Groups 1-5) (Fig. 2). Taken by themselves, the weak total mycolic acid 230 
profiles (Fig. 2) cannot be regarded as positive evidence for ancient tuberculosis. The constituents 231 
of the profiles are significantly smaller than those of standard M. tuberculosis, suggesting either 232 
considerable degradation or the presence of environmental mycobacteria. The former alternative is 233 
favoured, as the two specimens (grave Nos. 33, 212) that lacked any evidence of mycolipenate 234 
(ML) and mycocerosate (MC) biomarkers (Table 1), showed no evidence of any mycolates (Fig. 2). 235 
Given that assumption, the MA profiles provide background support for mycobacterial infection.  236 
The most positive evidence for the presence of tuberculosis resides in the MLs, which were 237 
found to be usually, as strong as, or stronger than the MCs, an exception being grave No. 88 with an 238 
excellent MC profile. Indeed in grave No. 154 the only lipid biomarker evidence is a very weak ML 239 
signal; this is probably genuine as aDNA was amplified from this sample.  240 
Of five classical tuberculosis cases (Table 1) with skeletal alterations characteristic for advanced 241 
stage TB, one only (grave No. 189) was positive for MTBC DNA with clear lipid biomarker 242 
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support (Fig. 2; Table 1). Four of the diagnosed classical TB cases were DNA negative. However, 243 
in three of these negative cases (grave Nos. 65, 90, 215) the diagnosis of skeletal tuberculosis was 244 
confirmed by lipid biomarker analysis with quite strong evidence (Fig. 2). For grave No. 38, lipid 245 
biomarker data were weak.  246 
For cases, showing atypical or early-stage TB lesions (Table 1), many of the biomarker results 247 
were inconsistent. The best lipid profiles (Group. 1) were recorded for grave Nos. 22, 86, 88 and 248 
134, but only the very fragmented material from grave No. 88 was supported by aDNA. 249 
Interestingly, grave No. 22 appeared to be a co-infection with tuberculosis and leprosy, the former 250 
being confirmed with a strong mycolipenate peak and the latter by C33 and C34 mycocerosates (Fig. 251 
2). The next Group 2 lipid biomarker level, with clear ML backed up by MCs in seven graves (Nos. 252 
12, 17, 48, 65, 90, 189, 215) was supported by aDNA in three atypical cases (grave Nos. 12, 17, 48) 253 
in addition to the classical case in grave No. 189 (Table 1). Only one (grave No. 66) of the two 254 
Group 3 biomarker level specimens had aDNA support, but both graves (Nos. 66, 188) had good 255 
ML backed up by weak but clear MCs. Dropping down to the single lipid biomarker Group 4 256 
representative (grave No. 154), as mentioned above, aDNA amplification was supported by a weak 257 
but clear ML. The four graves (Nos. 38, 92, 116, 233) assigned to lipid Group 5 had only minimal 258 
ML and MC evidence but aDNA was obtained from No. 92. Although grave No. 33 was MTBC 259 
DNA positive, negative lipid profiles were recorded. A juvenile male (grave No. 212.) was the only 260 
specimen showing atypical or early-stage TB lesions, where the biomolecular analyses gave 261 
negative results for the presence of both MTBC DNA and lipid biomarkers. The presence of 262 
mycolic acid biomarkers in material from grave No. 65 was previously suggested30 but the scientific 263 
basis for such a diagnosis has been dismissed.31  264 
Morphological assessment, detection of ancient DNA and demonstration of M. tuberculosis 265 
complex cell wall lipid markers proves there was widespread TB infection in this 8th century 266 
population. A variety of lesions at different stages of development were observed. The biomolecular 267 
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studies confirmed the presence of tuberculosis and lipid analysis also indicated a TB/leprosy 268 
coinfection. Our study highlights the difficulties of demonstrating TB in these individuals from over 269 
1300 years ago and the importance of using different methods is very clear. The relative success of 270 
lipid biomarkers compared with aDNA is probably due to their greater stability over time. This 271 
underlines the complementarity of morphological, aDNA and lipid biomarkers analyses in the 272 
diagnosis of ancient TB infections. 273 
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Figure legends 386 
Figure 1. Reverse phase fluorescence HPLC of total mycolates. The grave numbers are 387 
accompanied (in brackets) by the amount of sample analysed (mg). The “Lipid” column indicates 388 
the diagnostic power of mycolate (MA), mycolipenate (ML) and mycocerosate (MC) lipid 389 
biomarkers: ++++ (group 1), clear evidence of MA, ML and MC; +++ (group 2), clear ML signal 390 
with less strong MA and MC; ++ (group 3), good ML, weak MC and no MA; + (group 4), only a 391 
clear weak ML peak; +? (group 5), weak inconclusive ML and MC with some MA support; - 392 
(group 6), no evidence of mycobacterial lipids; ++++*, strong M. tuberculosis lipid signals with 393 
additional MC indicating M. leprae. The “aDNA” list records the presence of amplified DNA 394 
fragments. 395 
Figure 2.  Representative selected ion monitoring (SIM) negative ion-chemical ionization gas 396 
chromatography-mass spectrometry (NI-CI GC-MS) profiles of mycolipenate and mycocerosates. 397 
A, C, E grave Nos. 88 (Bristol University), 134 and 22 (Swansea University); B, C M. tuberculosis 398 
standard recorded at Bristol and Swansea, respectively; F, M. leprae standard recorded at Swansea. 399 
Ions monitored are exemplified by C27 m/z 407 and C27 m/z 409, representing C27 mycolipenate and 400 
C27 mycocerosate, respectively. Relative intensities (bold in brackets) are shown normalized to the 401 
major component (100).   402 
403 
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Table 1. Data for material investigated from Bélmegyer-Csömöki domb. 404 
CLASSICAL TB CASES 
Gr No sex age at death 
macromorphology 
aDNA 
lipid biomarkers 
  MA         ML       MC ST CT GT 
38 F 16‒18 ‒ + ‒ ‒    +              +?         +? 
65 F Maturus + ‒ ‒ ‒    +?            +           + 
90 M 57‒62 + + ‒ ‒    +              +           +? 
189 M 25‒28 + ‒ ‒ +    +              +           +? 
215 F 55‒60 ‒ ‒ + ‒    +?            +            + 
ATYPICAL (EARLY-STAGE) TB CASES 
Gr No sex age at death 
macromorphology 
aDNA 
lipid biomarkers 
 MA   ML   MC SVC RP EL LBP CO 
12 M 33‒39 ‒ +++ ‒ + ‒ +   +?     ++     +? 
17 M 22‒25 + + + + + +   +?     ++     +? 
22 undet. 16‒18 + ‒ + ‒ ‒ ‒   +       ++     + 
33 M 40‒45 + ‒ + + + +   ‒        ‒       ‒ 
48 M 55‒60 + + ‒ + (DP) ‒ +   +       +       + 
66 F 61‒67 + + ‒ ‒ ‒ +   ‒       +       +?   
86 M 59‒64 ‒ ‒ ‒ ‒ ‒ ‒   +       ++     + 
88 F 40‒45 ‒ +++ ‒ ‒ ‒ +   +       +       +++ 
92 M 20‒25 + +++ ‒ + ‒ +   +       +?     +? 
116 F 25‒30 ‒ +++ + +++ (DP) ‒ ‒   +       +?     +? 
134 F 16‒18 + ‒ ‒ ‒ + ‒   ++     +       + 
154 M 20‒24 + ‒ ‒ ‒ + +   ‒        +?     ‒ 
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188 undet. 7 + ‒ ‒ ‒ ‒ ‒   ‒        ++     + 
212 M 18‒20 + + ‒ ‒ ‒ ‒   ‒        ‒       ‒ 
233 F 23‒25 ‒ ‒ + ‒ ‒ ‒   +        +?     +? 
 405 
Gr No = grave No; F = female; M = male; undet. = undeterminable sex; ST = spondylitis 406 
tuberculosa; CT = coxitis tuberculosa; GT = gonitis tuberculosa; SVC = superficial vertebral 407 
changes; RP = rib periostitis; EL = endocranial lesions; LBP = long bone periostitis; CO = cribra 408 
orbitalia; DP = diffuse periostitis; MA = mycolates; ML = mycolipenate; MC = mycocerosates. 409 
410 
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SUPPLEMENTARY DATA 
Paleopathological analysis 
The distinction between classical and atypical or early-stage TB cases is shown in the figures below.  
Legend to Figure S1 
Classical TB cases 
a) Tuberculous spondylitis healed with gibbus formation (L1-L3) - Grave No. 65. (female, 
mature) 
b) Severe destruction of the 3rd vertebral body (inferior view) - Grave No. 65. (female, mature) 
c) Lumbosacral tuberculosis: severe erosion of the ventral sacral surface (traces of cold abscess) 
- Grave No. 90. (male, elderly) 
d) Coxitis tuberculosa: complete destruction and remodelling of the acetabulum - Grave No. 90. 
(male, elderly) 
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a) b) 
 
 
c) d)  
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Legend to Figure S2 
Atypical or early-stage TB changes 
a) Periosteal apposition on the visceral costal surface – Grave No. 88. (female, mature) 
b) Maze like surface excavation (serpens endocrania symmetrica)- Grave No. 233. (female, 
young adult) 
c) Abnormal vertebral vascularisation - Grave No. 92. (male, young adult) 
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a)      b) 
 
c) 
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Details of DNA extraction 
(a) Disaggregation of samples and DNA extraction 
A small quantity (22–78mg) of each sample was crushed by a sterile pestle in a mortar and 
added to 400µl of Proteinase K/EDTA. Samples were processed in batches of 7 plus a 
negative extraction control. The slurry was incubated at 56ºC24, and mixed on a bead beater 
daily. When the sample was solubilised, it was divided and one aliquot treated with 40µl of 
0.1mol1 of N-phenacylthiozolium bromide (PTB), to cleave any covalent cross-links thus 
enabling DNA strand separation and amplification21. Sample tube contents were transferred 
into separate 9ml tubes of NucliSens® (bioMérieux) lysis buffer containing 5mol1 
guanidium thiocyanate and incubated for 1–3 days at 56ºC. To complete the disruption of 
bone and any mycobacterial cell wall remnants, samples were boiled, then snap-frozen in 
liquid nitrogen and thawed in a 65ºC waterbath. This procedure was repeated twice. Sample 
tubes were centrifuged at 5000g for 15 min at 5ºC and the supernatants carefully removed 
into clean, sterile tubes. DNA was captured by adding 40µl silica suspension (NucliSens®) 
and mixing on a rotator wheel for 1 h. Tube contents were centrifuged and silica pellets 
washed once with wash buffer (NucliSens®), twice with 70% (v/v) ethanol (20ºC) and once 
with acetone (20ºC). After drying in a heated block, DNA was eluted using 60µl elution 
buffer (NucliSens®), aliquoted and used immediately or stored at 20ºC. Silica supernates 
(500µl) from PTB-negative samples were also collected from the 9ml tubes of lysis buffer, 
and the 2.0ml screw-capped Eppendorf tubes used to wash the silica. After chilling at 5ºC, 
supernates were mixed vigorously for 20 s with 200µl of Protein Precipitation Solution (SLS 
Ltd., UK) and centrifuged for 3min at 10,000g. Any pellet was discarded and 600µl 
isopropanol (20ºC) added to 550µl of each supernate. Tubes were mixed by inversion 50 
times and spun 3min. Supernates were discarded and tubes washed once with 500µl 70% 
ethanol (20ºC). After draining, tubes were dried in a heating block. Any precipitated DNA 
was re-hydrated with 60µl elution buffer (NucliSens®), aliquoted and used immediately or 
stored at 20ºC. Negative extraction controls were processed in parallel with the test 
samples.  
(b) DNA amplification and detection 
Two specific regions of the MTBC were targeted in the repetitive elements IS6110 (1–25 
copies/cell) and IS1081 (6 copies/cell). The IS6110 primers had a target region of 123 bp22 
and the IS1081 primers designed by Taylor et al.23 produce an amplicon of 113 bp. Later, 
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specific M. tuberculosis primers and a fluorescent probe were used24 to enable shorter DNA 
fragments to be detected in a real-time PCR reaction.  
(c) The PCR conditions 
The PCR mix included 2mM bovine serum albumin (BSA) to reduce PCR inhibition25 and 
2.0mM MgCl2. PCR assays were initially run at an annealing temperature of 58ºC and 
amplified DNA was examined by agarose gel electrophoresis.26 Subsequently, amplification 
was performed in a final volume of 25µl using a RotorGene© 3000 (Qiagen) real-time 
platform27, to enable the detection of DNA using SYBR Green and melt analysis or specific 
primers with fluorescent probe. Annealing was at 60ºC. A hot-start Taq polymerase was used 
to minimize non-specific primer and template binding. Negative DNA extraction and PCR 
controls were processed alongside the test samples.  
(d) Results 
Single-stage PCRs with outer primer pairs  
Gel with IS6110 PCR products     Gel with IS1081 PCR products 
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Key to abbreviations: 
EC = negative extraction control; s = silica supernate (fluid left in 2 ml tubes after silica spun 
down, normally short aDNA fragments); LVs = large volume silica supernate (fluid left in 9 
ml lysis buffer tubes after silica spun down, short aDNA fragments); wb = water blank 
negative control in PCR. 
Lanes (left to right): 1: Phi X-174 HaeIII markers; 11: 20bp and 100bp molecular markers 
Top row: 2: +ve control; 3: BC-12s; 4: BC-12 LVs; 5: wb1; 6: BC-17s; 7: BC-17 LVs; 8: BC-
22s; 9: wb2; 10: BC-22 LVs;  
Bottom row: 2: +ve control; 3: BC-33s; 4: BC-33 LVs; 5: BC-38s; 6: ECs; 7: BC-38 LVs; 8: 
BC-48s; 9: BC-48 LVs; 10: EC LVs;  
 
Conclusions: 
IS6110: possible weak positives with BC-12 LVs and BC-17 LVs. Positive with BC-33s. 
Non-specific bands from BC-12s, BC-22s, BC-33 LVs, and BC-48 LVs. Others negative. 
IS1081: positive with BC-12 LVs. All other samples (except positive controls) were negative 
 
Single-stage IS1081 PCRs using inner primers (113 bp) 
 
Lanes (left to right): 11: 20bp and 100bp molecular markers 
Top row: Lane 1: +ve control; 2: BC-12; 3: wb5; 4: BC-12+; 5: BC-17; 6: wb6; 7: BC-17+; 8: 
BC-22; 9: BC22+; 10: wb7. 
Bottom row: Lane 1: BC-33; 2: BC-33+; 3: BC-48; 4: wb8; 5: BC-48+; 6: EC; (lanes 7–10: 
different samples and another PCR) 
Conclusions: 
Positives from samples BC-12, BC-12+, BC-17, BC-17+, BC-48. 
Doubtful results from BC-22, BC-22+ (very faint trace) and BC-48+. 
Negatives from BC-33 and 33+, and all water blanks.  
BC-51 was examined separately for MTB IS1081 but was negative. 
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Nested IS6110 PCRs using inner primer pair 
 
 
 
Samples loaded in the same order as above, using the stage 1 PCR products that were re-
amplified for a further 25 cycles. 
Conclusions: 
Positive and negative controls were satisfactory. Only BC-33s was positive. 
Real-time experiments were also carried out with the same primers and melt analysis. Results 
are summarized at the end of the document. 
 
 
Real-time PCR with IS1081 primers and probe  
 
The lower the cycle threshold (Ct) the greater the quantity of target aDNA in the sample. In 
this image, the positive samples in order of their Ct was as follows: 
Positive control (a 1/10 dilution of extract from a Vác mummy) Ct 32 cycles 
BC-189+ (+ indicates the DNA was extracted using PTB) Ct 39 cycles 
Negatives were obtained from BC-12, BC-22, BC-116+, BC-116, BC-134+, BC-134, BC-
134s, BC-188+, BC-188, BC-189, BC-215, wb1, wb2, wb3, wb4, EC, EC1, EC+, ECs 
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In this experiment a nested PCR was performed on the PCR product from BC-189+ which 
explains the high level of signal at the start of the reaction. The positive control had a Ct of 28 
and sample BC-92 had a Ct of 41. 
Negatives were obtained from BC-22, BC-65+, BC-65, BC-66+, BC-66, BC86+, BC-86, BC-
88+, BC-88, BC-90+, BC-90, BC-92+, BC-154+, BC-154, wb1, wb2, wb3, wb4, EC+, EC. 
 
 
The positive control had a Ct of 28.6, BC-66s: 36.6, BC-86s: 36.9, BC-92: 36.0, BC-92s: 
36.3, and BC-154: 36.1. Individual screenshots are available for each positive sample. 
Negative results were obtained from BC-65s, BC-86s, BC-90s, wb, EC and ECs. 
These results were confirmed by agarose gel electrophoresis. 
 
Overall findings for M. tuberculosis complex in these samples 
Positives with one or both target regions: 
BC-12, BC-17, BC-33, BC-48, BC-66, BC-88, BC-92, BC-154, BC-189 
Negative (but cannot exclude poor preservation): 
BC-22, BC-38, BC-65, BC-86, BC-90, BC-116, BC-134, BC-188, BC-212, BC-215, BC-233 
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Analysis of mycolipenate and mycocerosates  
The initial analyses were performed at Bristol University, using a ThermoFinnigan 
MAT95 XP-Trap mass spectrometer, fitted with a Phenomenex Zebron ZB-5 (5% 
phenyl, 95% dimethylpolysiloxane) capillary column (30 m × 0.25 mm i.d. × 0.25 µm 
film thickness) using He as carrier gas (constant flow mode 1ml min-1) and ammonia 
as the CI reagent gas. A GC oven temperature gradient from 200 to 300ºC at 6.7ºC 
min-1 was used, the final temperature being held for 20 min. The ion source 
temperature was 250ºC, the injector 300ºC and the transfer line 300ºC. Selected ion 
monitoring (SIM) was used for mycocerosate ions at m/z 367.6311 (C24), 395.6844 
(C26), 409.7111 (C27), 437.7645 (C29), 451.7911 (C30), 479.8445 (C32), 493.8712 (C33) 
and 507.8978 (C34); additionally, m/z 407.6952 was monitored for the presence of C27 
mycolipenic acid. Later studies were carried out at Swansea University with the same 
Phenonemex Zebron ZB-5 column, using He as carrier gas. PFB esters, on NICI-
GCMS, fragment to produce negative carboxylate [M – H]- ions, which can be 
detected at high sensitivity. Selected ion monitoring (SIM) was used to search for 
mycocerosate carboxylate ions at m/z 367.6311 (C24), 395.6844 (C26), 409.7111 (C27), 
437.7645 (C29), 451.7911 (C30), 479.8445 (C32), 493.8712 (C33) and 507.8978 (C34).29 
Additionally, m/z 407.6952 was monitored for the presence of the C27 mycolipenate 
carboxylate ion.29 Partial racemisation of mycocerosates during the alkaline 
hydrolysis leads to the formation of diasteroisomers, which resolve on gas 
chromatography to give characteristic doublets; in contrast, mycolipenates are singlets 
as they cannot racemise.29  
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Legend to Figure S3 
Selected ion monitoring (SIM) negative ion chemical ionisation (NI-CI) gas chromatography 
mass spectrometry (GC-MS) of pentafluorobenzyl esters (Swansea University). A. Standard 
M. leprae (Swansea University); B-H.  Samples extracted from graves (BC) 22, 12, 17, 33, 38, 
65, 66, respectively. Intensities (bold in brackets) are normalised to the major component 
(100). 
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Legend to Figure S4 
Selected ion monitoring (SIM) negative ion chemical ionisation (NI-CI) gas chromatography 
mass spectrometry (GC-MS) of pentafluorobenzyl esters (Swansea University).  A. Standard 
M. tuberculosis (Strain C) (Swansea University); B-H.  Samples extracted from graves (BC) 
116, 134, 154, 188, 189, 212, 215, respectively. Intensities (bold in brackets) are normalised 
to the major component (100). 
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Legend to Figure S5 
Selected ion monitoring (SIM) negative ion chemical ionisation (NI-CI) gas chromatography 
mass spectrometry (GC-MS) of pentafluorobenzyl esters (Bristol University).  A-F.  Samples 
extracted from graves (BC) 48, 86, 88, 90, 92, 233, respectively. Intensities (bold in brackets) 
are normalised to the major component (100). 
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